3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Failure
1
Hepatitis C
1
Hepatitis B
1
Hepatic Insufficiency
1
HIV Infections
1
Carcinoma, Hepatocellular
1
Interventions
Cyclophosphamide
4
Cisplatin
3
pembrolizumab
2
fludarabine
2
apatinib
2
XELOX
2
S 1 (combination)
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Irinotecan
2
Injections
2
Gemcitabine
2
Fulvestrant
2
Epirubicin
2
Drug Therapy
2
Boron Neutron Capture Therapy
2
titanium silicide
1
tislelizumab
1
surufatinib
1
sintilimab
1
pegfilgrastim
1
nimotuzumab
1
ipatasertib
1
ferumoxides
1
famitinib
1
eribulin
1
dalpiciclib
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER_GOV
×
Raltegravir Potassium
×
Clear all
NCT01022476
2026-04-06
LIVERAL
ANRS, Emerging Infectious Diseases
Phase 1/2
Completed
14 enrolled